Clemastine Fumarate Activates Lipophagy to Promote Oligodendrocyte Progenitor Cells Differentiation and Remyelination in a Cuprizone-Induced Demyelination Model

Why It Matters

By targeting OPC lipid overload, clemastine could overcome a key barrier to remyelination, offering a disease‑modifying strategy for multiple sclerosis patients.

Key Takeaways

• Clemastine triggers lipophagy in OPCs, clearing lipid droplets
• Lipid clearance enhances OPC differentiation into mature oligodendrocytes
• In cuprizone mice, treatment restores myelin integrity
• Autophagy genes BECN1 and p62 modulated by clemastine
• Findings suggest repurposing antihistamine for MS remyelination therapy

Pulse Analysis

Multiple sclerosis often stalls at the remyelination stage because oligodendrocyte progenitor cells (OPCs) fail to mature. Recent work has linked this failure to the buildup of myelin‑derived lipid droplets within OPCs, which hampers their ability to differentiate. While clemastine fumarate, an antihistamine with muscarinic receptor antagonism, has already shown promise in accelerating remyelination, its impact on OPC lipid handling remained unexplored. Understanding whether the drug can modulate intracellular metabolism is critical for designing therapies that address the root cause of repair deficits.

The new study demonstrates that clemastine activates lipophagy, a selective form of autophagy that targets lipid droplets for degradation. In cultured OPCs exposed to myelin debris, the drug up‑regulated BECN1 and reduced p62 accumulation, leading to rapid clearance of intracellular lipids. This metabolic reset allowed OPCs to progress from a progenitor state to mature oligodendrocytes, as evidenced by increased expression of differentiation markers. Parallel experiments in cuprizone‑treated mice confirmed that systemic clemastine reduced brain lipid droplet burden, restored myelin sheath thickness, and boosted oligodendrocyte maturation in vivo.

These findings reposition clemastine from a symptomatic antihistamine to a disease‑modifying candidate for MS, highlighting lipid metabolism as a therapeutic lever. By clearing pathological lipids, the drug not only facilitates OPC maturation but may also mitigate inflammatory cascades linked to lipid‑laden microglia. The translational potential is bolstered by clemastine’s established safety profile and oral availability, paving the way for accelerated clinical trials focused on remyelination endpoints. Moreover, the study opens a broader avenue for targeting lipophagy in neurodegenerative disorders where lipid dysregulation impairs cellular repair.